E-viri
PDF
Recenzirano
Odprti dostop
-
Marcus, Robert; Davies, Andrew; Ando, Kiyoshi; Klapper, Wolfram; Opat, Stephen; Owen, Carolyn; Phillips, Elizabeth; Sangha, Randeep; Schlag, Rudolf; Seymour, John F; Townsend, William; Trněný, Marek; Wenger, Michael; Fingerle-Rowson, Günter; Rufibach, Kaspar; Moore, Tom; Herold, Michael; Hiddemann, Wolfgang
The New England journal of medicine, 10/2017, Letnik: 377, Številka: 14Journal Article
Obinutuzumab is an anti-CD20 antibody engineered to elicit killing mechanisms distinct from rituximab. In a trial of chemotherapy plus obinutuzumab or rituximab that used the antibody as maintenance therapy for 2 years, obinutuzumab prolonged progression-free survival.
